Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | OTC | P00480 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 7/20 | 0.34 |
| ▸ | NPY1R | P25929 | 5/20 | 0.34 |
| ▸ | NPY2R | P49146 | 4/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27484223 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP9 | |
| SCHEMBL31369271 | 0.96 | NOS2 (0.42) | NOS2NOS3NOS1DPP4DPP9 | |
| Arginine SCHEMBL7943591 | 0.86 | NOS2 (0.58) | NOS2NOS3NOS1OTCDDAH1 | |
| Arginine SCHEMBL1886681 | 0.86 | NOS2 (0.58) | NOS2NOS3NOS1OTCDDAH1 | |
| SCHEMBL9952947 | 0.83 | NOS3 (0.41) | NOS2NOS3NOS1DPP7OTC | |
| SCHEMBL27382578 | 0.83 | NOS3 (0.41) | NOS2NOS3NOS1DPP7OTC | |
| Hydrochloric Acid SCHEMBL8063762 | 0.82 | NOS3 (0.41) | NOS2NOS3NOS1DPP7OTC | |
| Arginine SCHEMBL27682442 | 0.82 | NOS2 (0.53) | NOS2NOS3NOS1OTCDDAH1 | |
| SCHEMBL9614818 | 0.82 | NOS3 (0.39) | NOS2NOS3NOS1DPP4DPP9 | |
| SCHEMBL29774200 | 0.81 | NOD1 (0.40) | NOS2NOS3NOS1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | claimed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| US-20220242914-A1 | PEPTIDES AND USE THEREOF | SYNTHERIX LIMITED (GB) | 2022-08-04 | — | — | US | claimed |
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| WO-2024200264-A1 | PEPTIDES AND USES THEREOF | SYNTHERIX LIMITED (GB) | 2024-10-03 | — | — | WO | disclosed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-20220242914-A1 | PEPTIDES AND USE THEREOF | SYNTHERIX LIMITED (GB) | 2022-08-04 | — | — | US | disclosed |
| CN-1171116-A | N-substituted glycine derivatives as factor Xa inhibitors | CORVAS INT INC (US) | 1998-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | NPR1, NPR3, PTMS | NOS2 2667/4885NOS3 1210/4885NOS1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.